View Cart  

Health Canada May Allow Drug Sponsors to Skirt Human Bioavailability Studies

A A
Drug sponsors may be able to avoid establishing in vivo bioequivalence as part of safety and efficacy data requirements in situations where in vitro data provide a reasonable estimate of the relative in vivo performance of the two products, according to new Health Canada draft guidance.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00